Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Martin van den Bent; M Klein; Marion Smits; JC Reijneveld; Pim French; P Clement; FYF de Vos; A Wick; PJ Mulholland; MJB Taphoorn; J Lewis; M Weller; OL Chinot; J.M. Kros; Iris de Heer; T Verschuere; C Coens; V Golfinopoulos; T Gorlia; A Idbaih

doi:10.1016/s1470-2045(18)30362-0

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Martin van den Bent, M Klein, Marion Smits, JC Reijneveld, Pim French, P Clement, FYF de Vos, A Wick, PJ Mulholland, MJB Taphoorn, J Lewis, M Weller, OL Chinot, J.M. Kros, Iris de Heer, T Verschuere, C Coens, V Golfinopoulos, T Gorlia, A Idbaih

Research output: Contribution to journal › Article › Academic › peer-review

73 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1170-1179
Number of pages	10
Journal	Lancet Oncology
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/s1470-2045(18)30362-0
Publication status	Published - 2018

Access to Document

10.1016/s1470-2045(18)30362-0

http://hdl.handle.net/1765/114110

Cite this

van den Bent, M., Klein, M., Smits, M., Reijneveld, JC., French, P., Clement, P., de Vos, FYF., Wick, A., Mulholland, PJ., Taphoorn, MJB., Lewis, J., Weller, M., Chinot, OL., Kros, J. M., de Heer, I., Verschuere, T., Coens, C., Golfinopoulos, V., Gorlia, T., & Idbaih, A. (2018). Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, 19(9), 1170-1179. https://doi.org/10.1016/s1470-2045(18)30362-0

@article{0e41b67016fe430eb7dca5ae60d2cc69,

title = "Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial",

author = "{van den Bent}, Martin and M Klein and Marion Smits and JC Reijneveld and Pim French and P Clement and {de Vos}, FYF and A Wick and PJ Mulholland and MJB Taphoorn and J Lewis and M Weller and OL Chinot and J.M. Kros and {de Heer}, Iris and T Verschuere and C Coens and V Golfinopoulos and T Gorlia and A Idbaih",

year = "2018",

doi = "10.1016/s1470-2045(18)30362-0",

language = "Undefined/Unknown",

volume = "19",

pages = "1170--1179",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

van den Bent, M, Klein, M, Smits, M, Reijneveld, JC, French, P, Clement, P, de Vos, FYF, Wick, A, Mulholland, PJ, Taphoorn, MJB, Lewis, J, Weller, M, Chinot, OL, Kros, JM , de Heer, I, Verschuere, T, Coens, C, Golfinopoulos, V, Gorlia, T & Idbaih, A 2018, 'Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial', Lancet Oncology, vol. 19, no. 9, pp. 1170-1179. https://doi.org/10.1016/s1470-2045(18)30362-0

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. / van den Bent, Martin; Klein, M; Smits, Marion et al.
In: Lancet Oncology, Vol. 19, No. 9, 2018, p. 1170-1179.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

AU - van den Bent, Martin

AU - Klein, M

AU - Smits, Marion

AU - Reijneveld, JC

AU - French, Pim

AU - Clement, P

AU - de Vos, FYF

AU - Wick, A

AU - Mulholland, PJ

AU - Taphoorn, MJB

AU - Lewis, J

AU - Weller, M

AU - Chinot, OL

AU - Kros, J.M.

AU - de Heer, Iris

AU - Verschuere, T

AU - Coens, C

AU - Golfinopoulos, V

AU - Gorlia, T

AU - Idbaih, A

PY - 2018

Y1 - 2018

U2 - 10.1016/s1470-2045(18)30362-0

DO - 10.1016/s1470-2045(18)30362-0

M3 - Article

SN - 1470-2045

VL - 19

SP - 1170

EP - 1179

JO - Lancet Oncology

JF - Lancet Oncology

IS - 9

ER -